文献速递淋巴瘤

滤泡性淋巴瘤包含生发中心样和记忆样分子亚型且具有预后意义

Follicular lymphoma comprises germinal center-like and memory-like molecular subtypes with prognostic significance.
PubMed 文献 · Blood · 2024-01-01

基于RELEVANCE试验中接受利妥昔单抗-化疗或利妥昔单抗-来那度胺治疗的滤泡性淋巴瘤患者肿瘤样本,通过RNA测序等识别出记忆B细胞和生发中心B细胞两种基因表达特征,构建20基因预测器FL20将患者分为记忆样(n=160)和生发中心样(n=164)亚型;在化疗组记忆样亚型无进展生存期显著更短(HR 2.13,P=0.0023),而来那度胺组两亚型无进展生存期相当,提示来那度胺联合方案对记忆样亚型有获益(HR 0.54,P=0.011)。

要点

  • FL20将滤泡性淋巴瘤分为记忆样和生发中心样两个分子亚型,突变谱不同。
  • 化疗组中记忆样亚型无进展生存期显著短于生发中心样(HR 2.13,P=0.0023)。
  • 来那度胺联合组两亚型无进展生存期相当,对记忆样亚型优于化疗(HR 0.54,P=0.011)。

核心结论

  • 滤泡性淋巴瘤可分为生物学和临床风险不同的记忆样与生发中心样亚型,FLcm检测可用于常规临床实践识别可能从非化疗方案(如来那度胺联合)获益的记忆样患者。

研究设计与样本

  • 分析RELEVANCE试验中接受利妥昔单抗-化疗或利妥昔单抗-来那度胺治疗的新诊断滤泡性淋巴瘤患者的肿瘤样本,采用RNA测序、DNA测序、免疫组化和/或荧光原位杂交。
  • 通过无监督基因聚类识别记忆B细胞和生发中心B细胞两种基因表达特征,合并为20基因预测器FL20进行分类。
  • 在独立滤泡性淋巴瘤队列GSE119214(n=137)中验证FL20的预后价值。
  • 开发使用FOXP1、LMO2、CD22和MUM1抗体的免疫组化算法FLcm。

主要发现

  • FL20将患者分为记忆样亚型(n=160)和生发中心样亚型(n=164),两亚型突变谱不同。
  • 化疗组中记忆样亚型无进展生存期显著短于生发中心样亚型(HR 2.13,P=0.0023)。
  • 来那度胺联合组两亚型无进展生存期相当,来那度胺联合较化疗对记忆样亚型有获益(HR 0.54,P=0.011)。
  • FL20的预后价值在独立化疗队列GSE119214(n=137)中得到验证。
  • FLcm免疫组化算法与FL20预后相关显著。

临床怎么用

  • 作者认为FLcm检测可用于常规临床实践,识别可能从非化疗方案(如来那度胺联合)获益的记忆样滤泡性淋巴瘤患者。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

A robust prognostic and biological classification for newly diagnosed follicular lymphoma (FL) using molecular profiling remains challenging. FL tumors from patients treated in the RELEVANCE trial with rituximab-chemotherapy (R-chemo) or rituximab-lenalidomide (R2) were analyzed using RNA sequencing, DNA sequencing, immunohistochemistry (IHC), and/or fluorescence in situ hybridization. Unsupervised gene clustering identified 2 gene expression signatures (GSs) enriched in normal memory (MEM) B cells and germinal center (GC) B-cell signals, respectively. These 2 GSs were combined into a 20-gene predictor (FL20) to classify patients into MEM-like (n = 160) or GC-like (n = 164) subtypes, which also displayed different mutational profiles. In the R-chemo arm, patients with MEM-like FL had significantly shorter progression-free survival (PFS) than patients with GC-like FL (hazard ratio [HR], 2.13; P = .0023). In the R2 arm, both subtypes had comparable PFS, demonstrating that R2 has a benefit over R-chemo for patients with MEM-like FL (HR, 0.54; P = .011). The prognostic value of FL20 was validated in an independent FL cohort with R-chemo treatment (GSE119214 [n = 137]). An IHC algorithm (FLcm) that used FOXP1, LMO2, CD22, and MUM1 antibodies was developed with significant prognostic correlation with FL20. These data indicate that FL tumors can be classified into MEM-like and GC-like subtypes that are biologically distinct and clinically different in their risk profile. The FLcm assay can be used in routine clinical practice to identify patients with MEM-like FL who might benefit from therapies other than R-chemo, such as the R2 combination. This trial was registered at www.clinicaltrials.gov as #NCT01476787 and #NCT01650701.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Laurent C, Trisal P, Tesson B, et al. Follicular lymphoma comprises germinal center-like and memory-like molecular subtypes with prognostic significance. Blood. 2024. PMID: 39374535. doi:10.1182/blood.2024024496

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。